;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Lexicon, JDRF deal

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas JDRF, New York, N.Y. Business: Endocrine/Metabolic Lexicon said JDRF will provide funding to support a double-blind, placebo-controlled trial of 400 mg …

    Published on 8/18/2014
  • MacroGenics, Servier deal

    MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. Servier, Neuilly-sur-Seine, France Business: Cancer MacroGenics will receive a $5 million milestone payment from Servier under a 2012 deal granting Servier an exclusive …

    Published on 8/18/2014
  • MannKind, Sanofi deal

    MannKind Corp. (NASDAQ:MNKD), Valencia, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Endocrine/Metabolic MannKind granted Sanofi exclusive, worldwide rights to develop and commercialize Afrezza to …

    Published on 8/18/2014
  • MonoSol Rx, Galena Biopharma deal

    MonoSol Rx LLC, Warren, N.J. Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Business: Gastrointestinal MonoSol granted Galena exclusive, U.S. rights to Zuplenz ondansetron oral soluble film. The selective serotonin…

    Published on 8/18/2014
  • MorphoSys, Galapagos deal

    MorphoSys AG (Xetra:MOR;Pink:MPSYF), Martinsried, Germany Galapagos N.V. (Euronext:GLPG;Pink:GLPYY), Mechelen, Belgium Business: Inflammation Galapagos and MorphoSys said the first program under the companies 2008 deal …

    Published on 8/18/2014
  • Pfizer, Puma Biotechnology deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Puma Biotechnology Inc. (NYSE:PBYI), Los Angeles, Calif. Business: Cancer Puma and Pfizer amended a 2011 deal under which Puma has exclusive, worldwide rights to develop and …

    Published on 8/18/2014
  • Rush University Medical Center, DRI Capital deal

    Rush University Medical Center, Chicago, Ill. DRI Capital Inc., Toronto, Ontario Business: Autoimmune DRI Capitals private equity fund Drug Royalty III acquired worldwide royalty rights to Ampyra dalfampridine from Rush…

    Published on 8/18/2014
  • Sanofi, Zai Lab deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Zai Laboratory Inc., Shanghai, China Business: Pulmonary, Inflammation Sanofi granted newco Zai worldwide rights to develop, manufacture and commercialize two preclinical …

    Published on 8/18/2014
  • Taris, Allergan deal

    Taris Biomedical Inc., Lexington, Mass. Allergan Inc. (NYSE:AGN), Irvine, Calif. Business: Genitourinary Allergan acquired Taris lead program, LiRIS, for $67.5 million in cash up front and up to $520 million in …

    Published on 8/18/2014
  • Topotarget, BioAlliance deal

    Topotarget A/S, Copenhagen, Denmark BioAlliance Pharma S.A., Paris, France Business: Cancer Cancer companies BioAlliance and Topotarget completed their merger in a stock deal. The new company is Onxeo S.A. (Euronext:…

    Published on 8/18/2014
  • Tris Pharma, Vernalis Group deal

    Tris Pharma Inc., Monmouth Junction, N.J. Vernalis Group plc (LSE:VER), Wokingham, U.K. Business: Pulmonary, Drug delivery The partners said Tris achieved a milestone under a February 2012 deal granting Vernalis …

    Published on 8/18/2014
  • Universite de Montreal, AmorChem deal

    Universite de Montreal, Montreal, Quebec AmorChem L.P., Montreal, Quebec Business: Cardiovascular The Universite de Montreal granted VC fund AmorChem exclusive, worldwide rights to a program targeting CD36 (GPIV) to …

    Published on 8/18/2014
  • University of Tokyo, Qiagen deal

    University of Tokyo, Tokyo, Japan Qiagen N.V. (Xetra:QIA;NASDAQ:QGEN), Venlo, the Netherlands Business: Diagnostic The university granted Qiagen exclusive, worldwide rights to splicing factor 3B subunit 1 (SF3B1). …

    Published on 8/18/2014
  • Agreen Biotech Co. Ltd., Cellular Biomedicine deal

    Agreen Biotech Co. Ltd., China Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Business: Supply/Service, Cancer Cellular will acquire Chinese cancer supply/service company Agreen in a cash and stock …

    Published on 8/11/2014
  • AutoGenomics, Genomas deal

    AutoGenomics Inc., Vista, Calif. Genomas Inc., Hartford, Conn. Business: Diagnostic, Pharmacogenetics AutoGenomics and Genomas partnered to develop genetic tests and DNA-guided diagnostic systems to optimally select …

    Published on 8/11/2014
  • Berry Genomics, Illumina deal

    Berry Genomics Co. Ltd., Beijing, China Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Business: Genomics Berry said it selected Illuminas NextSeq 500 Sequencing System as the next-generation sequencing (NGS) technology…

    Published on 8/11/2014
  • Bial-Portela, moksha8 deal

    Bial-Portela & Ca. S.A., S. Mamede do Coronado, Portugal moksha8 Pharmaceuticals Inc., Wayne, Pa. Business: Neurology Bial-Portela granted moksha8 an exclusive license to commercialize epilepsy treatment Zebinix …

    Published on 8/11/2014
  • Boehringer Ingelheim, Medivir deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Infectious Boehringer Ingelheim granted Medivir exclusive, worldwide rights to develop and commercialize compounds that …

    Published on 8/11/2014
  • Bristol-Myers, Allied Minds plc deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Allied Minds plc (LSE:ALM), Boston, Mass. Business: Pharmaceuticals Bristol-Myers and Allied Minds formed jointly-owned new company Allied-Bristol Life Sciences LLC to…

    Published on 8/11/2014
  • Cancer Research UK, Astellas deal

    Cancer Research UK, London, U.K. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Cancer Research UK and its Cancer Research Technology Ltd. commercial arm partnered with Astellas to identify and …

    Published on 8/11/2014
  • Cara, Maruishi deal

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Maruishi Pharmaceutical Co. Ltd., Osaka, Japan Business: Neurology Cara earned a $500,000 milestone payment from Maruishi under a 2013 deal granting Maruishi …

    Published on 8/11/2014
  • Charleston Laboratories, Daiichi Sankyo deal

    Charleston Laboratories Inc., Jupiter, Fla. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Neurology Charleston and Daiichi Sankyo partnered to develop and commercialize Charlestons fixed-dose combination …

    Published on 8/11/2014
  • Clinuvel, Retrophin deal

    Clinuvel Pharmaceuticals Ltd. (ASX:CUV;Xetra:UR9), Melbourne, Australia Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Dermatology Clinuvel rejected an unsolicited July proposal from Retrophin to acquire …

    Published on 8/11/2014
  • DiNonA, 3SBio deal

    DiNonA Inc., Seoul, South Korea 3SBio Inc., Shenyang, China Business: Cancer DiNonA granted 3SBio exclusive rights to develop and commercialize leukotuximab in Taiwan and China, including Hong Kong and Macau, and in the…

    Published on 8/11/2014
  • Helsinn, Chugai deal

    Helsinn Healthcare S.A., Lugano, Switzerland Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Gastrointestinal Helsinn granted Chugais Chugai Pharma Marketing Ltd. subsidiary exclusive …

    Published on 8/11/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993